Physiological changes associated with pregnancy may alter antiretroviral plasma concentrations and might jeopardize prevention of mother-to-child HIV transmission. Lopinavir is one of the protease inhibitors more frequently prescribed during pregnancy in Europe. We described the free and total pharmacokinetics of lopinavir in HIV-infected pregnant and non-pregnant women, and evaluated whether significant alterations in its disposition and protein binding warrant systematic dosage adjustment.
Methods
Plasma samples were collected at first, second and third trimester of pregnancy, at delivery, in umbilical cord and postpartum. Lopinavir free and total plasma concentrations were measured by HPLC-MS/MS. Bayesian calculations were used to extrapolate total concentrations to trough (Cmin).
Results
A total of 42 HIV-positive pregnant women and 37 non-pregnant women on lopinavir/ritonavir were included in the study. Compared to postpartum and control values, total lopinavir Cmin was decreased moderately (31–39%) during pregnancy, and free Cmin minimally, showing significant alteration only at delivery (-35%). However, total and free Cmin remained in all patients above the target concentrations for wild-type virus of 1,000 ng/ml, and above the unbound IC50WT of 0.64–0.77 ng/ml of lopinavir, respectively. Lopinavir free fractions remained higher during pregnancy compared to post-partum and controls, and were influenced by α-1-acid-glycoprotein and albumin decrease. Free cord-to-mother ratio (0.43) was 2.7-fold higher than total cord-to-mother ratio (0.16), suggesting higher fetal exposure.
Conclusions
The moderate decrease of total lopinavir concentrations during pregnancy is not associated with proportional decrease in free concentrations. Both reach a nadir at delivery, albeit not to an extent that would put treatment-naive women at risk of insufficient exposure to the free, pharmacologically active concentrations of lopinavir. No dosage adjustment is therefore needed during pregnancy as it is unlikely to further enhance treatment efficacy but could potentially increase the risk of maternal and fetal toxicity. Nonetheless, in case of viral resistance in treatment-experienced pregnant women, loss of virological control or questionable adherence, it is justified to consider lopinavir dosage adjustment based on total plasma concentration measurement.
References
1.
ThorneC., NewellM-LPrevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis2004; 17: 247–252.
2.
SempriniA.E., FioreS.HIV and pregnancy: is the outlook for mother and baby transformed?Curr Opin Obstet Gynecol2004; 16: 471–475.
3.
NewellM-L, ThorneC.Antiretroviral therapy and mother-to-child transmission of HIV-1. Expert Rev Anti Infect Ther2004; 2: 717–732.
4.
Bellón CanoJ.M., Sánchez-RamónS., CiriaL.The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain. Med Sci Monit2004; 10: CR179–CR184.
5.
WattsD.H., CovingtonD.L., BeckermanK.Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol2004; 191: 985–992.
6.
RakhmaninaN.Y., Van den AnkerJ.N., SoldinS.J.Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther Drug Monit2004; 26: 110–115.
7.
ThorneC., NewellM-LSafety of agents used to prevent mother-to-child transmission of HIV. Drug Saf2007; 30: 203–213.
8.
MirochnickM.Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci2000; 918: 287–297.
9.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission.Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 14 September 2011. Accessed 12 January 2012). Available from http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
10.
LoebsteinR., LalkinA., KorenG.Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet1997; 33: 328–343.
11.
IsrailiZ.H., DaytonP.G.Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev2001; 33: 161–235.
12.
StekA.M., MirochnickM., CapparelliE.Reduced lopinavir exposure during pregnancy. AIDS2006; 20: 1931–1939.
13.
PeytavinG., Pierre-FrançoisS., CassardB.Reduced lopinavir exposure during pregnancy: a case control study.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 579.
14.
AweekaF.T., StekA., BestB.M.Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med2010; 11: 232–238.
15.
ManaviK., McDonaldA., Al-SharquiA.Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS2007; 21: 643–645.
16.
ElseL.J., DouglasM., DickinsonL., BackD.J., KhooS.H., TaylorG.P.Improved bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother2012; 56: 816–824.
17.
LambertJ.S., ElseL.J., JacksonV.Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med2011; 12: 166–173.
18.
GauthierJ., BoucherM., HigginsN., MoreauJ., YangH., SheehanN.L.Therapeutic drug monitoring of lopinavir/ ritonavir (tablet formulation) in pregnancy.10th International Workshop on Clinical Pharmacology of HIV Therapy. 15–17 April 2009, Amsterdam, the Netherlands. Abstract P49.
19.
BaroncelliS., VillaniP., FloridiaM.Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens. Ther Drug Monit2008; 30: 604–610.
20.
RamautarsingR.A., van der LugtJ., GorowaraM.Thai HIV-1 infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS2011; 25: 1299–1303.
21.
MirochnickM., BestB.M., StekA.M.Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr2008; 49: 485–491.
22.
BestB.M., StekA.M., MirochnickM.Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Aquir Immune Defic Syndr2010; 54: 381–388.
23.
KeiserO., Gayet-AgeronA., RudinC.Antiretroviral treatment during pregnancy. AIDS2008; 22: 2323–2330.
24.
BackD., GattiG., FletcherC.Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS2002; 16Suppl 1: S5–S37.
25.
KappelhoffB.S., CrommentuynK.M., de MaatM.M., MulderJ.W., HuitemaA.D., BeijnenJ.H.Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet2004; 43: 845–853.
26.
BoffitoM., BackD.J., BlaschkeT.F.Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses2003; 19: 825–835.
27.
WrightJ.D., BoudinotF.D., UjhelyiM.R.Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet1996; 30: 445–462.
28.
RowlandM.Protein binding and drug clearance. Clin Pharmacokinet1984; 9: 10–17.
29.
AndersonG.D.Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet2005; 44: 989–1008.
30.
MirochnickM., CapparelliE.Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet2004; 43: 1071–1087.
31.
FrederiksenM.C.Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol2001; 25: 120–123.
32.
BoffitoM., AcostaE., BurgerD.Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther2005; 10: 375–392.
33.
Swiss HIV Cohort Study Website. (Updated November 2012. Accessed 4 February 2013.) Available from http://www.shcs.ch.
34.
ColomboS., BeguinA., TelentiA.Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2005; 819: 259–276.
35.
KKGT.Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie, Association for Quality Assessment in TDM and clinical Toxicology, The Hague, the Netherlands. (Accessed 4 February 2013.) Available from http://www.kkgt.nl/English%20Version.htm.
36.
FayetA., BéguinA., Martinez de TejadaB.Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit2008; 30: 511–522.
37.
LubomirovR., di IulioJ., FayetA.ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics2010; 20: 217–230.
38.
Bouillon-PichaultM., JullienV., AzriaE.Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother2009; 63: 1223–1232.
39.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Updated 14 October 2011. Accessed 12 January 2012). Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
40.
BreilhD., PellegrinI., RouzésA.Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS2004; 18: 1305–1310.
41.
Khuong-JossesM.A., AzeradD., BoussairiA., EkoukouD.Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin Trials2007; 8: 254–255.
42.
IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials Group Website. (Accessed 12 January 2012). Available from http://www.impaactgroup.org.
43.
PattersonK.B., DumondJ.B., PrinceH.A.Pharmacokinetics of the lopinavir/ritonavir tablet in HIV-infected pregnant women: a longitudinal investigation of protein bound and unbound drug exposure with empiric dosage adjustment.18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 645.
44.
BoffitoM., HoggardP.G., LindupW.E.Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit2004; 26: 35–39.
45.
MarzoliniC., RudinC., DecosterdL.A.Transplacental passage of protease inhibitors at delivery. AIDS2002; 16: 889–893.
46.
SymeM.R., PaxtonJ.W., KeelanJ.A.Drug transfer and metabolism by the human placenta. Clin Pharmacokinet2004; 43: 487–514.
47.
GulatiA., BoudinotF.D., GerkP.M.Binding of lopinavir to human α1-acid glycoprotein and serum albumin. Drug Metab Dispos2009; 37: 1572–1575.
48.
GuiducciC.ISyPeM: Intelligent Integrated Systems for Personalised Medicine. (Accessed 4 February 2013.) Available from http://www.nano-tera.ch/projects/405.php.
